Literature DB >> 28449457

Nomogram prediction for the survival of the patients with small cell lung cancer.

Hui Pan1,2,3,4, Xiaoshun Shi5, Dakai Xiao2,3, Jiaxi He1,2, Yalei Zhang1,2, Wenhua Liang1,2, Zhi Zhao4, Zhihua Guo1,2, Xusen Zou1,2, Jinxin Zhang4, Jianxing He1,2.   

Abstract

BACKGROUND: Small cell lung cancer (SCLC) is a subtype of lung cancer with poor prognosis. In this study, we aimed to build a nomogram to predict the survival of individual with SCLC by incorporating significant clinical parameters.
METHODS: The patients with SCLC were enrolled from the First Affiliated Hospital of Guangzhou Medical University (GMUFAH) between 2009 and 2013. We identified and incorporated the independent prognostic factors to build a nomogram to predict the survival of SCLC patients. The predictive accuracy and discriminative ability of the nomogram were evaluated by concordance index (C-index) and calibration curve. We also compared the accuracy of the built model with the 7th AJCC TNM and VALSG staging system. The nomogram was further validated in an independent cohort of 80 patients with SCLC from Cancer Center of Guangzhou Medical University (GMUCC) between 2009 and 2013.
RESULTS: A total of 275 patients with SCLC were included in the primary cohort, and seven independent prognostic factors were identified including age, N stage, metastasis status, histology, platelets to lymphocyte ratio (PLR), neuron specific enolase (NSE) and CYFRA21-1 as independent prognostic factors after using Cox regression model. A nomogram incorporating these prognostic factors was subsequently built. The calibration curves for possibilities of 1-, 2-year overall survival (OS) revealed optimal agreement between nomogram prediction and actual observation. The C-index of this nomogram was higher than that of TNM and VALSG staging system in both primary and validation cohort (nomogram vs. TNM, primary cohort 0.68 vs. 0.65, P<0.01, validation cohort 0.66 vs. 0.62, P<0.05; nomogram vs. VALSG, primary cohort 0.68 vs. 0.66, P<0.01, validation cohort 0.66 vs. 0.64, P<0.05).
CONCLUSIONS: In this study, we established and validated a novel nomogram for the prediction of OS for the patients with SCLC. This model could provide more accurate individual prediction of survival probability of SCLC than the existing staging systems.

Entities:  

Keywords:  Small cell lung cancer (SCLC); nomogram; prediction; survival

Year:  2017        PMID: 28449457      PMCID: PMC5394048          DOI: 10.21037/jtd.2017.03.121

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  29 in total

Review 1.  Predictive and prognostic factors in small cell lung cancer: current status.

Authors:  D Yip; P G Harper
Journal:  Lung Cancer       Date:  2000-06       Impact factor: 5.705

Review 2.  Nomograms in oncology: more than meets the eye.

Authors:  Vinod P Balachandran; Mithat Gonen; J Joshua Smith; Ronald P DeMatteo
Journal:  Lancet Oncol       Date:  2015-04       Impact factor: 41.316

3.  Development and validation of a nomogram for predicting survival in patients with resected non-small-cell lung cancer.

Authors:  Wenhua Liang; Li Zhang; Gening Jiang; Qun Wang; Lunxu Liu; Deruo Liu; Zheng Wang; Zhihua Zhu; Qiuhua Deng; Xinguo Xiong; Wenlong Shao; Xiaoshun Shi; Jianxing He
Journal:  J Clin Oncol       Date:  2015-01-26       Impact factor: 44.544

4.  Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America.

Authors:  Pasi A Jänne; Boris Freidlin; Scott Saxman; David H Johnson; Robert B Livingston; Frances A Shepherd; Bruce E Johnson
Journal:  Cancer       Date:  2002-10-01       Impact factor: 6.860

5.  Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer--what limits limited disease?

Authors:  Patrick Micke; Andreas Faldum; Tsegay Metz; Kai-Michael Beeh; Fernando Bittinger; Jan-Georg Hengstler; Roland Buhl
Journal:  Lung Cancer       Date:  2002-09       Impact factor: 5.705

6.  Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.

Authors:  Martin Peifer; Lynnette Fernández-Cuesta; Martin L Sos; Julie George; Danila Seidel; Lawryn H Kasper; Dennis Plenker; Frauke Leenders; Ruping Sun; Thomas Zander; Roopika Menon; Mirjam Koker; Ilona Dahmen; Christian Müller; Vincenzo Di Cerbo; Hans-Ulrich Schildhaus; Janine Altmüller; Ingelore Baessmann; Christian Becker; Bram de Wilde; Jo Vandesompele; Diana Böhm; Sascha Ansén; Franziska Gabler; Ines Wilkening; Stefanie Heynck; Johannes M Heuckmann; Xin Lu; Scott L Carter; Kristian Cibulskis; Shantanu Banerji; Gad Getz; Kwon-Sik Park; Daniel Rauh; Christian Grütter; Matthias Fischer; Laura Pasqualucci; Gavin Wright; Zoe Wainer; Prudence Russell; Iver Petersen; Yuan Chen; Erich Stoelben; Corinna Ludwig; Philipp Schnabel; Hans Hoffmann; Thomas Muley; Michael Brockmann; Walburga Engel-Riedel; Lucia A Muscarella; Vito M Fazio; Harry Groen; Wim Timens; Hannie Sietsma; Erik Thunnissen; Egbert Smit; Daniëlle A M Heideman; Peter J F Snijders; Federico Cappuzzo; Claudia Ligorio; Stefania Damiani; John Field; Steinar Solberg; Odd Terje Brustugun; Marius Lund-Iversen; Jörg Sänger; Joachim H Clement; Alex Soltermann; Holger Moch; Walter Weder; Benjamin Solomon; Jean-Charles Soria; Pierre Validire; Benjamin Besse; Elisabeth Brambilla; Christian Brambilla; Sylvie Lantuejoul; Philippe Lorimier; Peter M Schneider; Michael Hallek; William Pao; Matthew Meyerson; Julien Sage; Jay Shendure; Robert Schneider; Reinhard Büttner; Jürgen Wolf; Peter Nürnberg; Sven Perner; Lukas C Heukamp; Paul K Brindle; Stefan Haas; Roman K Thomas
Journal:  Nat Genet       Date:  2012-09-02       Impact factor: 38.330

7.  Surveillance epidemiology and end results evaluation of the role of surgery for stage I small cell lung cancer.

Authors:  James B Yu; Roy H Decker; Frank C Detterbeck; Lynn D Wilson
Journal:  J Thorac Oncol       Date:  2010-02       Impact factor: 15.609

Review 8.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

9.  The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer.

Authors:  M H Kang; S-I Go; H-N Song; A Lee; S-H Kim; J-H Kang; B-K Jeong; K M Kang; H Ling; G-W Lee
Journal:  Br J Cancer       Date:  2014-06-12       Impact factor: 7.640

10.  Pretreatment Albumin/Globulin Ratio Predicts the Prognosis for Small-Cell Lung Cancer.

Authors:  Ting Zhou; Xiaobo He; Wenfeng Fang; Jianhua Zhan; Shaodong Hong; Tao Qin; Yuxiang Ma; Jin Sheng; Ningning Zhou; Yuanyuan Zhao; Yan Huang; Li Zhang
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

View more
  18 in total

1.  The association between plasma fibrinogen levels and lung cancer: a meta-analysis.

Authors:  Ke Zhang; Ye Xu; Shanyue Tan; Xueyan Wang; Mulong Du; Lingxiang Liu
Journal:  J Thorac Dis       Date:  2019-11       Impact factor: 2.895

2.  Prognostic Nomogram for Overall Survival in Small Cell Lung Cancer Patients Treated with Chemotherapy: A SEER-Based Retrospective Cohort Study.

Authors:  Min Liang; Mafeng Chen; Shantanu Singh; Shivank Singh
Journal:  Adv Ther       Date:  2021-11-03       Impact factor: 3.845

3.  Nomograms to Predict Individual Prognosis of Patients with Primary Small Cell Carcinoma of the Bladder.

Authors:  Fan Dong; Yifan Shen; Fengbin Gao; Xiao Shi; Tianyuan Xu; Xianjin Wang; Xiaohua Zhang; Shan Zhong; Minguang Zhang; Shanwen Chen; Zhoujun Shen
Journal:  J Cancer       Date:  2018-03-08       Impact factor: 4.207

4.  Surgical Management and Prognostic Prediction of Adenocarcinoma of Jejunum and Ileum.

Authors:  Xin Xie; Zhangjian Zhou; Yongchun Song; Chengxue Dang; Hao Zhang
Journal:  Sci Rep       Date:  2017-11-09       Impact factor: 4.379

5.  Prognostic value of neuron-specific enolase for small cell lung cancer: a systematic review and meta-analysis.

Authors:  Zhoujunyi Tian; Chaoyang Liang; Zhenrong Zhang; Huanshun Wen; Hongxiang Feng; Qianli Ma; Deruo Liu; Guangliang Qiang
Journal:  World J Surg Oncol       Date:  2020-05-30       Impact factor: 2.754

6.  A novel approach to determine two optimal cut-points of a continuous predictor with a U-shaped relationship to hazard ratio in survival data: simulation and application.

Authors:  Yimin Chen; Jialing Huang; Xianying He; Yongxiang Gao; Gehendra Mahara; Zhuochen Lin; Jinxin Zhang
Journal:  BMC Med Res Methodol       Date:  2019-05-09       Impact factor: 4.615

7.  Neutrophil-lymphocyte ratio is prognostic in early stage resected small-cell lung cancer.

Authors:  Zoltan Lohinai; Laura Bonanno; Aleksei Aksarin; Alberto Pavan; Zsolt Megyesfalvi; Balazs Santa; Virag Hollosi; Balazs Hegedus; Judit Moldvay; PierFranco Conte; Mikhail Ter-Ovanesov; Evgeniy Bilan; Balazs Dome; Glen J Weiss
Journal:  PeerJ       Date:  2019-07-29       Impact factor: 2.984

8.  Nomogram to predict cause-specific mortality in extensive-stage small cell lung cancer: A competing risk analysis.

Authors:  Jia Zhong; Qiwen Zheng; Tongtong An; Jun Zhao; Meina Wu; Yuyan Wang; Minglei Zhuo; Jianjie Li; Xinghui Zhao; Xue Yang; Bo Jia; Hanxiao Chen; Zhi Dong; Jingjing Wang; Yujia Chi; Xiaoyu Zhai; Ziping Wang
Journal:  Thorac Cancer       Date:  2019-07-18       Impact factor: 3.500

9.  Survival and pretreatment prognostic factors for extensive-stage small cell lung cancer: A comprehensive analysis of 358 patients.

Authors:  Li-Ling Huang; Xing-Sheng Hu; Yan Wang; Jun-Ling Li; Hong-Yu Wang; Peng Liu; Jian-Ping Xu; Xiao-Hui He; Xue-Zhi Hao; Pei-Di Jiang; Yu-Tao Liu; Jian Luo; Sheng-Yu Zhou; Jin-Wan Wang; Jian-Liang Yang; Yan Qin; Peng Yuan; Lin Lin; Yuan-Kai Shi
Journal:  Thorac Cancer       Date:  2021-05-09       Impact factor: 3.500

10.  Development and validation of a prognostic model of resectable small-cell lung cancer: a large population-based cohort study and external validation.

Authors:  Yu Wang; Zhaofei Pang; Xiaowei Chen; Tao Yan; Jichang Liu; Jiajun Du
Journal:  J Transl Med       Date:  2020-06-15       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.